SHR-6508
- Generic Name
- SHR-6508
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
Phase 2
Active, not recruiting
- Conditions
- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 303
- Registration Number
- NCT06236295
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of SHR6508 in Secondary Hyperparathyroidism
Phase 2
Active, not recruiting
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05663411
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath